Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin
Open Access
- 30 November 2004
- journal article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 10 (11), 772-783
- https://doi.org/10.1016/j.bbmt.2004.07.005
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantationBlood, 2004
- P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cellsBlood, 2002
- Acute graft-versus-host disease: inflammation run amok?JCI Insight, 2001
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxisBone Marrow Transplantation, 1999
- Specific depletion of alloreactive T cells in HLA‐identical siblings: a method for separating graft‐versus‐host and graft‐versus‐leukaemia reactionsBritish Journal of Haematology, 1998
- Immunohistochemical Study of Skin Lesions in Acute and Chronic Graft Versus Host Disease Following Bone Marrow TransplantationThe American Journal of Surgical Pathology, 1997
- A TOXICITY STUDY OF TRIMETREXATE USED IN COMBINATION WITH CYCLOSPORINE AS ACUTE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN HLA-MISMATCHED, RELATED DONOR BONE MARROW TRANSPLANTSTransplantation, 1995
- An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.The Journal of Experimental Medicine, 1994
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987